Abstract
Linezolid has emerged as an important therapeutic option for the treatment of Staphylococcus aureus in patients with cystic fibrosis. We report the rapid emergence, upon treatment with linezolid, of linezolid-resistant S. aureus clinical isolates through the accumulation of resistance-associated 23S rRNA mutations, together with acquisition of an altered mutator phenotype.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides
-
Adult
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Cystic Fibrosis / drug therapy
-
Cystic Fibrosis / genetics
-
Cystic Fibrosis / microbiology*
-
Humans
-
Linezolid
-
Oxazolidinones
-
RNA, Ribosomal, 23S / genetics
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / genetics
-
Staphylococcus aureus / pathogenicity
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Oxazolidinones
-
RNA, Ribosomal, 23S
-
Linezolid